CC-90006
Drug
Celgene Corporation
Total Payments
$716,710
Transactions
9
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $224,023 | 5 | 0 |
| 2018 | $492,687 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $710,080 | 8 | 99.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,630 | 1 | 0.9% |
Payments by Type
Research
$710,080
8 transactions
General
$6,630
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CC-90006-CP-002 - A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 Administered Subcuta | Celgene Corporation | $492,687 | 0 |
| A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 Administered Subcutaneously in Patients with Plaque-type Psoriasis (CC-90006-CP-002) | Celgene Corporation | $217,393 | 0 |
Top Doctors Receiving Payments for CC-90006
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $716,710 | 9 |
Ad
Manufacturing Companies
- Celgene Corporation $716,710
Product Information
- Type Drug
- Total Payments $716,710
- Total Doctors 0
- Transactions 9
About CC-90006
CC-90006 is a drug associated with $716,710 in payments to 0 healthcare providers, recorded across 9 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $224,023 was paid across 5 transactions to 0 doctors.
The most common payment nature for CC-90006 is "Unspecified" ($710,080, 99.1% of total).
CC-90006 is associated with 2 research studies, including "CC-90006-CP-002 - A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 Administered Subcuta" ($492,687).